Trial Profile
A randomised phase II double-blinded placebo-controlled trial of intravenous immunoglobulins and rituximab in patients with antibody-associated psychosis (SINAPPS2)
Status:
Recruiting
Phase of Trial:
Phase II
Latest Information Update: 09 Apr 2024
Price :
$35
*
At a glance
- Drugs Immunoglobulin G (Primary) ; Rituximab (Primary)
- Indications Psychotic disorders
- Focus Therapeutic Use
- Acronyms SINAPPS2
- 26 Jan 2024 Planned End Date changed from 31 Mar 2024 to 31 Mar 2026.
- 26 Jan 2024 Planned primary completion date changed from 31 Oct 2023 to 31 Mar 2026.
- 08 Nov 2022 Planned number of patients changed from 80 to 70.